We are trailblazers, tenaciously deciphering human biology.

Fabric Genomics is working to ensure precision medicine is the standard of care for all patients

Our tools enable scientists to quickly and accurately process and analyze whole genomes, exomes and gene panels. Fabric Genomics’ cutting-edge genomic data processing and advanced algorithmic tools have been licensed by over 1,000 academic institutions and clinical laboratories around the world.

Fabric Genomics can complete genetic analysis of whole genomes in less than 1 hour. Leading organizations have achieved causative candidate yields of up to to 54%. Fabric Genomics’ core customers are commercial clinical laboratories, hospital core labs, country sequencing programs, and research institutions.

Timeline
Ensuring Precision Healthcare Becomes a Standard Clinical Practice

2009

Omicia founded by Martin Reese, Edward Kiruluta, John Stuelpnagel & Paul Billings

December 2013

Omicia raises $8.3M Series A round of financing and transitions focus from research to clinical market

July 2015

Omicia is selected as a primary genomic interpretation and clinical reporting provider in the UK's 100,000 Genomes Project (Genomics England)

June 2016

Omicia raises $23M Series B round of financing from renowned strategic investors

January 2017

Omicia announces somatic cancer capabilities and acquires secondary analysis firm Spiral Genetics (adds Seattle office)

March 2017

Omicia rebrands to Fabric Genomics to signal launch of fully-integrated and comprehensive genomic data analysis platform for all NGS testing

Our Team

Martin Reese, Ph.D.

Founder, President, and CEO

Martin Reese, Ph.D.

Founder, President, and CEO

Dr. Reese is an internationally recognized expert and entrepreneur in Genomics and Bioinformatics. Prior to founding Fabric Genomics, Martin served as Vice President of Discovery Informatics for ValiGen, and co-founded Neomorphic, where he served as President and Chief Scientific Officer. The human genome annotation software that Martin developed at Neomorphic, provided the foundation for the successful commercialization of microarrays by Affymetrix. During his career he has been actively involved in community-wide assessments of genome annotation. He organized the state-of-the-art Genome Annotation Assessment Project and was a member of the Berkeley Drosophila Genome Project, which provided the essential proof-of-concept platform for “shotgun” sequencing technology. At the Lawrence Berkeley National Laboratories Martin developed gene-finding algorithms for the Human Genome Project. He holds a Masters degree in Medical Informatics from the University of Heidelberg and a Ph.D. in Genetics jointly from the University of Hohenheim, Germany and the University of California, Berkeley.

Edward Kiruluta

Co-Founder and Chief Technology Officer

Edward Kiruluta

Co-Founder and Chief Technology Officer

Edward is responsible for product development, operations, and IT at Fabric Genomics. Previously, Edward was the Vice President of Development at Symyx Technologies, Inc., where he was responsible for the development of Symyx Notebook. From 2005-2008 Edward was the Vice President of Engineering at DemandTec where he led the Econometrics, Operations Research, and Database teams and saw the company through a successful IPO. Prior to this he was Senior Director of Informatics at Merck Research Labs (where he led the development of the Target Genome Index), and Chief Technology Officer at DoubleTwist, where his team developed Prophecy, the first comprehensive annotation of the human genome, and DoubleTwist.com, the first web portal for life science researchers. Edward studied Electrical Engineering at Memorial University in Canada.

Paul Billings, M.D., Ph.D.

Co-Founder and Chief Medical Officer

Paul Billings, M.D., Ph.D.

Co-Founder and Chief Medical Officer

Dr. Billings serves as Chief Medical Officer at Fabric Genomics. Prior to joining Fabric Genomics, Dr. Billings was CMO at Life Technologies, acquired by Thermo Fisher Scientific, Inc. (NYSE: TMO). Before that he was founding and acting Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital. Dr. Billings served as President, CEO and Director of CELLective Dx Corporation. Dr. Billings currently serves on the Scientific Advisory Board of the FDA, the Genomic Medicine Advisory Committee at the Dept. of Veterans Affairs, and the National Academy of Sciences Institute of Medicine’s Roundtable on Genomics. He was Deputy Chief of Staff and Chief of General Medicine at the Palo Alto VA Healthcare System and Stanford Medical School, and then CMO and Deputy Network Director of VISN 17 in the Department of Veterans Affairs. He has been Professor of Anthropology (adjunct) at UC Berkeley and has published extensively on topics in immunology, genetics and medicine. Dr. Billings received an A.B. summa cum laude from UC San Diego, and both his M.D. and Ph.D. degrees from Harvard University.

Ivy Chan

CFO

Ivy Chan

CFO

Charlene Son Rigby

SVP, Customer Operations

Charlene Son Rigby

SVP, Customer Operations

Charlene is responsible for customer operation at Fabric Genomics. Charlene has spent her career building businesses at the intersection of data, technology and life sciences. Previous to Fabric Genomics, she was responsible for all go-to-market activities at Metamarkets, a big data analytics startup. Prior to Metamarkets, Charlene was Vice President of Business Planning at Oracle where she rolled out Analytics for the sales organization, and Executive Director of Sales Operations at Siebel Systems, a $2B license business. She also led product management at DoubleTwist, a bioinformatics startup. Charlene started her career as a neuroscience researcher at Syntex (acquired by Roche). She holds a B.A. in Human Biology from Stanford University and an M.B.A. from the Haas School of Business at U.C. Berkeley.

Mathias Klozenbuecher

VP, Business Development

Mathias Klozenbuecher

VP, Business Development

Mathias is responsible for all Business Development activities at Fabric Genomics. His responsibilities include 3rd party partnerships, strategic alliances, licensing and co-development opportunities. Prior to joining Fabric Genomics, Mathias was the Head of Strategy, Business Development and Strategic Procurement for the Siemens Healthcare Molecular Diagnostics Business. In this role Mathias led all M&A activities, defined and implemented a short term revenue growth- and long term technology based business unit strategy and led all strategic procurement activities. Before that Mathias held several leadership positions within Siemens Healthcare including Marketing where he increased his products’ market share in the double digits within 12 months, Project Management where he executed a savings program bringing in over $150M in efficiencies per year, and being a member of the Diagnostics Executive Leadership Team, a $5B part of Siemens Healthcare. Mathias holds a B.A. and a M.S. in Genetics and Microbiology from the University of Vienna, Austria and from UCLA.

Dave Anstey

Head of Sales

Dave Anstey

Head of Sales

Laurel Katz

Head of Design

Laurel Katz

Head of Design

Laurel provides design leadership, strategy, and execution for experiences across Fabric Genomics. She defines and drives the direction of design and the vision for the brand. Laurel is responsible for creating a cohesive and compelling design system across brand, marketing and product. Previous to Fabric Genomics, she was Director of Design at Practice Fusion, a cloud base healthcare platform. At Practice Fusion, Laurel led a rebranding of the company including reimagining the product experience. Laurel started her career as a designer at advertising agencies in New York including FCB Global and J. Walter Thompson. Laurel holds a B.A in Critical Theory and Contemporary Aesthetics from Yale College and a B.S. from Art Center College of Design.

Adina Mangubat

Director, Secondary Analysis Innovation

Adina Mangubat

Director, Secondary Analysis Innovation

Adina Mangubat is responsible for product development, business development, and the management of the Secondary Analysis Team. Prior to Fabric Genomics, Adina was the CEO and co-founder of Spiral Genetics, a leader in the bioinformatics secondary analysis market. At Spiral Genetics, she led complex sales to highly technical audiences, drove business development and product vision, and built a diverse team of highly talented technical and scientific individuals to develop the world’s most advanced bioinformatics technology. In addition, she was the primary catalyst for creating a transparent, high integrity, and mission-driven culture. Early in her career, Adina worked with two other high-technology companies wherein her role included team development, brand development, marketing, channel development and sales for complex technologies.
A graduate of the University of Washington, Adina holds a B.S. in Psychology with a focus on Entrepreneurship and was recognized by the Washington Biotechnology and Biomedical Association as one of the 2013 Women to Watch in Life Science. Additionally, she was featured in Forbes 2013 “30 under 30″ for Science and Healthcare. Adina’s passion for world-changing technology, coupled with her adept entrepreneurial focus and clear team development skills have enabled her to bring the Fabric Genomics Secondary Analysis technology to the forefront of bioinformatics innovation.

Melanie Babcock

Clinical Services

Melanie Babcock

Clinical Services

Cheryl Bellavia

Product

Cheryl Bellavia

Product

Jeremy Bruestle

Development

Jeremy Bruestle

Development

Birgit Crain

Field Application Scientist

Birgit Crain

Field Application Scientist

Adam English

Development

Adam English

Development

Benjamin Fagin

Development

Benjamin Fagin

Development

Marco Falcioni

Development

Marco Falcioni

Development

Anthony Fejes

Development

Anthony Fejes

Development

Robert Flickenger

Development

Robert Flickenger

Development

Erwin Frise

Development

Erwin Frise

Development

Mahsa Ghafourian

Development

Mahsa Ghafourian

Development

Joshua Grigonis

Development

Joshua Grigonis

Development

Andrew Guo

Product

Andrew Guo

Product

Kyle Hart

Clinical Genomics Program Management

Kyle Hart

Clinical Genomics Program Management

Lisa Herta

Customer Success Engineer

Lisa Herta

Customer Success Engineer

Carol Horowitz

Technical Writer

Carol Horowitz

Technical Writer

Brittnee Jones

Field Application Scientist

Brittnee Jones

Field Application Scientist

Ritu Kamal

Product

Ritu Kamal

Product

Eric Kofman

Development

Eric Kofman

Development

Kristin Mayer

Development

Kristin Mayer

Development

Nils McCarthy

Development

Nils McCarthy

Development

Vanisha Mistry

Field Application Scientist

Vanisha Mistry

Field Application Scientist

Gigi Nguyen

Administration

Gigi Nguyen

Administration

Sahar Nohzadeh-Malakshah

Development

Sahar Nohzadeh-Malakshah

Development

Marcella Rierson

Sales

Marcella Rierson

Sales

Jeffrey Rule

Development

Jeffrey Rule

Development

Vanessa B. Sawyer

Marketing

Vanessa B. Sawyer

Marketing

Niranjan Shekar

Field Application Scientist

Niranjan Shekar

Field Application Scientist

Peter Spiro

Development

Peter Spiro

Development

Björn Stade

Development

Björn Stade

Development

Scott Temple

Development

Scott Temple

Development

Milo Toor

Development

Milo Toor

Development

Kelsey Valentine

Business Development

Kelsey Valentine

Business Development

Board

In addition to Martin Reese, Fabric Genomics’ board members are:

John Stuelpnagel, D.V.M.

Co-Founder, Chairman of the Board of Directors

John Stuelpnagel, D.V.M.

Co-Founder, Chairman of the Board of Directors

Dr. Stuelpnagel currently serves as the Executive Chairman of Ariosa Diagnostic since 2009 and a board member at Sequenta, two leading genomic-based Diagnostic companies in the San Francisco bay area. Prior to this, John co-founded Illumina Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and biological function.
John was involved in making Illumina one of the most successful life science companies, serving as its first President and Chief Executive Officer from 1998 to 1999, Vice President of Business Development from 1999 to 2002, Senior Vice President of Operations from 2002 to 2005 and Chief Operating Officer from January 2005 to April 2008.
Prior, he was a venture capitalist at CW Group from 1997 to 1998 and with Catalyst Partners, a venture capital firm, from 1996 to 1997. While at CW Group, John uncovered what would become Illumina’s BeadArray technology at Tufts University and negotiated an exclusive license to that technology which led to the founding of Illumina Inc. He also served as a member of the Board of Directors of Illumina Inc. from April 1998 until April 2008. John received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.

Mike A. Aicher

Board of Directors

Mike A. Aicher

Board of Directors

Mike co-founded and served as National Genetics Institute’s (NGI) CEO since 1991. NGI became a wholly owned subsidiary of Laboratory Corporation of America (NASDAQ: LH) in 2000, where he held various positions.
He ran the company’s “Esoteric Business Units”, which generated over $1 billion in annual revenue. Mike holds a Bachelor of Science in Business Administration from the University of Redlands, a Master of Business Administration in Economics from Columbus University and is a certified Global Biotechnology Executive from the University of California, Berkeley. He also received Ernst and Young’s “Entrepreneur of the Year” award for emerging technologies.

Tad Buchanan

Board of Directors

Tad Buchanan

Board of Directors

Tad co-founded the investment firm of Buchanan Investments, Inc. in 1998 with his father, Mike. Together, they have founded, invested in and raised equity and debt capital for numerous companies, including DM&E Railroad, Central Montana Resources, Opti Canada, White Oak Resources, AlphaClone, TabletCommand, Gensys Software, Tri Alpha Energy, OneSun Solar, and numerous other private companies.
Prior to founding Buchanan Investments, Inc., Tad was an Executive Director at UBS Securities with primary responsibility for managing Asian equity sales and trading based in NY. He was also an equity analyst at UBS and W.I. Carr (Far East), Ltd. based in Hong Kong, with responsibility for covering financial services, software, industrial and energy companies in Indonesia, Thailand, India, Pakistan, Sri Lanka and Bangladesh. Prior to joining W.I. Carr (Far East) Ltd., Tad was a credit analyst within the Corporate Lending Group of Wells Fargo Bank. He graduated from Pepperdine University with a B.A. in Economics and from Boston College with an M.B.A, International Finance. He currently serves on the boards of Central Montana Resources, AlphaClone, Tablet Command, and OneSun Solar. Tad is also a board observer of Tri Alpha Energy. He is married with three children, and is a Trustee of Marin Country Day School in Corte Madera, CA.

Matt Posard

Board of Directors

Matt Posard

Board of Directors

Matt has over 25 years of general management and commercial experience in the life sciences, molecular diagnostics and genomics industry. Mr. Posard held influential leadership roles with market leading companies including Illumina, Trovagene, Biosite / Alere, and Gen-Probe.
Matt has a distinguished reputation in commercializing transformative novel products and technology in the genomics space. Mr. Posard holds a B.A. degree in Quantitative Economics and Decision Science from the University of California, San Diego and currently serves as a board member for Halozyme Therapeutics, SlipChip Corporation, Dermtech Inc., and Envision Genomics.

Investors